Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration

European Journal of Pharmaceutical Sciences

Volumn 92, Issue , 2016, Pages 287-297

  Rodríguez Villanueva, Javier ^a   Bravo Osuna, Irene ^b   Herrero Vanrell, Rocío ^b   Molina Martínez, Irene Teresa ^b   Guzmán Navarro, Manuel ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Controlled release; Dexamethasone; Human serum albumin; Intraocular administration; Microspheres; PLGA; Stability

Indexed keywords

DEXAMETHASONE; HUMAN SERUM ALBUMIN; MICROSPHERE; POLYGLACTIN; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; DELAYED RELEASE FORMULATION; GLUCOCORTICOID; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SERUM ALBUMIN;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; ADMINISTRATION AND DOSAGE; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG RELEASE; DRUG STORAGE; HELA CELL LINE; INTRAVITREAL DRUG ADMINISTRATION; MOUSE; PHARMACOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CELL LINE; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DRUG LIBERATION; DRUG STABILITY; DRUG STORAGE; GLUCOCORTICOIDS; HELA CELLS; HUMANS; INTRAVITREAL INJECTIONS; LACTIC ACID; MICE; MICROSPHERES; POLYGLYCOLIC ACID; SERUM ALBUMIN; VITAMIN E;

EID: 84979934318     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2016.03.012     Document Type: Article

References (60)

1. 2004/23/EC, 2004 2004/23/EC, European Parliament and the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. 2004.
2. Albanese, A., Chan, W.C., Effect of gold nanoparticle aggregation on cell uptake and toxicity. ACS Nano 5:7 (2011), 5478–5489.
3. Anand, A., Sharma, K., Using current data to define new approach in age related macular degeneration: need to accelerate translational research. Curr. Genomics 15:4 (2014), 266–277.
4. Andres-Guerrero, V., Zong, M., et al. Novel biodegradable polyesteramide microspheres for controlled drug delivery in ophthalmology. J. Control. Release 211 (2015), 105–117.
5. Aubert-Pouessel, A., Bibby, D.C., A novel in vitro delivery system for assessing the biological integrity of protein upon release from PLGA microspheres. Pharm. Res. 19:7 (2002), 1046–1051.
6. Avery, R., Intravitreal Injection Technique And Monitoring Updated Guidelines of an Expert Panel. Retin. J., 34(Suppl. 12), 2014.
7. Barcia, E., Herrero-Vanrell, R., Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp. Eye Res. 89:2 (2009), 238–245.
8. Barcia, E., Herradon, C., Herrero-Vanrell, R., Biodegradable additives modulate ganciclovir release rate from PLGA microspheres destined to intraocular administration. Lett. Drug Des. 2 (2005), 184–193.
9. Behar-Cohen, F., Drug Delivery to the Vitreous Humor. Ocular Drug Delivery, Systems Barriers and Application of Nanoparticulate Systems, 2013, CRC Press, Florida.
10. Bertram, J.P., Rauch, M.F., Using polymer chemistry to modulate the delivery of neurotrophic factors from degradable microspheres: delivery of BDNF. Pharm. Res. 27:1 (2010), 82–91.
11. Bolitho, C., Bayl, P., The anti-apoptotic activity of albumin for endothelium is mediated by a partially cryptic protein domain and reduced by inhibitors of G-coupled protein and PI-3 kinase, but is independent of radical scavenging or bound lipid. J. Vasc. Res. 44:4 (2007), 313–324.
12. Checa-Casalengua, P., Jiang, C., Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. J. Control. Release 156:1 (2011), 92–100.
13. Cho, E.R., Kang, S.W., Poly(lactic-co-glycolic acid) microspheres as a potential bulking agent for urological injection therapy: preliminary results. J. Biomed. Mater. Res. B Appl. Biomater. 72:1 (2005), 166–172.
14. Chovatiya, R., Medzhitov, R., Stress, inflammation, and defense of homeostasis. Mol. Cell 54:2 (2014), 281–288.
15. Coccoli, V., Luciani, A., Engineering of poly(epsilon-caprolactone) microcarriers to modulate protein encapsulation capability and release kinetic. J. Mater. Sci. Mater. Med. 19:4 (2008), 1703–1711.
16. Comyn, O., Lightman, S.L., Corticosteroid intravitreal implants vs. ranibizumab for the treatment of vitreoretinal disease. Curr. Opin. Ophthalmol. 24:3 (2013), 248–254.
17. Davis, M.E., The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6:3 (2009), 659–668.
18. Dunne, M.M., Ramtoola, Z., Fluphenazine release from biodegradable microparticles: characterization and modelling of release. J. Microencapsul. 26:5 (2009), 403–410.
19. Engin, K.N., Alpha-tocopherol: looking beyond an antioxidant. Mol. Vis. 15 (2009), 855–860.
20. Fernandez-Carballido, A., Puebla, P., Radiosterilisation of indomethacin PLGA/PEG-derivative microspheres: protective effects of low temperature during gamma-irradiation. Int. J. Pharm. 313:1–2 (2006), 129–135.
21. Francis, G.L., Albumin and mammalian cell culture: implications for biotechnology applications. Cytotechnology 62:1 (2010), 1–16.
22. Fratoddi, I., The puzzle of toxicity of gold nanoparticles. The case-study of HeLa cells. Toxicol. Res. 4:4 (2015), 796–800.
23. Garbayo, E., Ansorena, E., Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. Eur. J. Pharm. Biopharm. 69:3 (2008), 844–851.
24. Garbayo, E., Montero-Menei, C.N., Effective GDNF brain delivery using microspheres—a promising strategy for Parkinson's disease. J. Control. Release 135:2 (2009), 119–126.
25. Gaudana, R., et al. Ocular drug delivery. AAPS J. 12:3 (2010), 348–360.
26. Gavini, E., Rassu, G., Spray-dried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide. Eur. J. Pharm. Biopharm. 68:2 (2008), 245–252.
27. Giteau, A., Venier-Julienne, M.C., How to achieve sustained and complete protein release from PLGA-based microparticles?. Int. J. Pharm. 350:1–2 (2008), 14–26.
28. Gonciarz, A., Kus, K., Capillary electrophoresis/frontal analysis versus equilibrium dialysis in dexamethasone sodium phosphate-serum albumin binding studies. Electrophoresis 33:22 (2012), 3323–3330.
29. Halliwell, B., Whiteman, M., Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. Br. J. Pharmacol. 142:2 (2004), 231–255.
30. He, J.T., et al. Stabilization and encapsulation of a staphylokinase variant (K35R) into poly(lactic-co-glycolic acid) microspheres. Int. J. Pharm. 309 (2006), 101–108.
31. Herrero-Vanrell, R., Bravo-Osuna, I., The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies. Prog. Retin. Eye Res. 42 (2014), 27–43.
32. Huang, X., Li, N., Quantitative three-dimensional analysis of poly (lactic-co-glycolic acid) microsphere using hard X-ray nano-tomography revealed correlation between structural parameters and drug burst release. J. Pharm. Biomed. Anal. 112 (2015), 43–49.
33. Jiang, C., Moore, M.J., Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol. Vis. 13 (2007), 1783–1792.
34. Klose, D., Siepmann, F., How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int. J. Pharm. 314:2 (2006), 198–206.
35. Lee, B.K., Yun, Y.H., Fabrication of drug-loaded polymer microparticles with arbitrary geometries using a piezoelectric inkjet printing system. Int. J. Pharm. 427:2 (2012), 305–310.
36. Madsen, C.G., Skov, A., Simple measurements for prediction of drug release from polymer matrices — solubility parameters and intrinsic viscosity. Eur. J. Pharm. Biopharm. 92 (2015), 1–7.
37. Martinez-Sancho, C., Herrero-Vanrell, R., Poly (D,L-lactide-co-glycolide) microspheres for long-term intravitreal delivery of aciclovir: influence of fatty and non-fatty additives. J. Microencapsul. 20:6 (2003), 799–810.
38. Martinez-Sancho, C., Herrero-Vanrell, R., Vitamin A palmitate and aciclovir biodegradable microspheres for intraocular sustained release. Int. J. Pharm. 326:1–2 (2006), 100–106.
39. Miserocchi, E., Fogliato, G., Review on the worldwide epidemiology of uveitis. Eur. J. Ophthalmol. 23:5 (2013), 705–717.
40. Nita, M., Grzybowski, A., Age-related macular degeneration in the aspect of chronic low-grade inflammation (pathophysiological parainflammation). Mediat. Inflamm., 2014, 2014, 930671.
41. Rafi, M., Singh, S.M., Controlled release of bioactive recombinant human growth hormone from PLGA microparticles. J. Microencapsul. 27:6 (2010), 552–560.
42. Rodrigues, L.B., Leite, H.F., In vitro release and characterization of chitosan films as dexamethasone carrier. Int. J. Pharm. 368:1–2 (2009), 1–6.
43. Rodríguez, J., Guzmán, M., Preliminary studies on HSA microparticles to modulate dexamethasone release. 2013, CRS Chapter Congress, Valencia.
44. Sah, H., Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. J. Control. Release 58:2 (1999), 143–151.
45. Sampat, K.M., Garg, S.J., Complications of intravitreal injections. Curr. Opin. Ophthalmol. 21:3 (2010), 178–183.
46. Sapieha, P., Hamel, D., Proliferative retinopathies: angiogenesis that blinds. Int. J. Biochem. Cell Biol. 42:1 (2010), 5–12.
47. Schiller, M., Franz, S., Hypothesis: human serum-borne albumin bound lipids promote cellular survival after apoptosis induction by a variety of stimuli. Apoptosis 13:2 (2008), 319–328.
48. Schmidt, S., Gonzalez, D., Significance of protein binding in pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 99:3 (2010), 1107–1122.
49. Shah, V.P., Tsong, Y., In vitro dissolution profile comparison–statistics and analysis of the similarity factor, f2. Pharm. Res. 15:6 (1998), 889–896.
50. Sherif, Z., Pleyer, U., Corticosteroids in ophthalmology: past–present–future. Ophthalmologica 216:5 (2002), 305–315.
51. Short, B.G., Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol. Pathol. 36:1 (2008), 49–62.
52. Srivastava, S., Kumar, R., Modified release biodegradable polymeric microspheres of stavudine: cell viability, cellular uptake, hemolysis studies and in vivo pharmacokinetics. Curr. HIV Res. 13:6 (2015), 503–516.
53. van Wijngaarden, P., Qureshi, S.H., Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Clin. Exp. Optom. 91:5 (2008), 427–437.
54. Wang, M., A spheres-in-sphere structure for improving protein-loading poly (lactide-co-glycolide) microspheres. Polym. Degrad. Stab. 95 (2010), 6–13.
55. Wang, Y., Gu, B., Microspheres prepared with PLGA blends for delivery of dexamethasone for implantable medical devices. Pharm. Res. 31:2 (2014), 373–381.
56. Yao, J., Tucker, B.A., Robust cell integration from co-transplantation of biodegradable MMP2-PLGA microspheres with retinal progenitor cells. Biomaterials 32:4 (2011), 1041–1050.
57. Yasukawa, T., Tabata, Y., Recent advances in intraocular drug delivery systems. Recent Pat. Drug Deliv. Formul. 5:1 (2011), 1–10.
58. Yeh, M.K., Chen, J.L., The preparation of sustained release erythropoietin microparticle. J. Microencapsul. 24:1 (2007), 82–93.
59. Yuan, W., Wu, F., Development of protein delivery microsphere system by a novel S/O/O/W multi-emulsion. Eur. J. Pharm. Sci. 36:2–3 (2009), 212–218.
60. Zhang, X., Zeng, H., Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci., 4, 2014, 27.